Jianchang Lin

3.1k citations

84 papers · 1.0k indexed · 1 hit paper · h-index 18

Oncology top 10%
Pulmonary and Respiratory Medicine top 10%
Molecular Biology
Statistics and Probability top 1%
Hematology top 5%

Co-authors: Veronica Bunn Shu JinQing LiDanny Nguyen Minal Mehta Huamao Mark Lin Rachael Liu Pasi A. Jänne
Topics: Statistical Methods in Clinical Trials (44 papers)Lung Cancer Treatments and Mutations (21 papers)Optimal Experimental Design Methods (19 papers)
Cited by: Statistics and Probability Hematology Oncology
Journals: Journal of Clinical Oncology Blood Biometrics
Partner nations: United States Japan China

In The Last Decade

Jianchang Lin

76 papers receiving 983 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations Danny Nguyen, Shu Jin et al. profile →

Peers

Countries citing papers authored by Jianchang Lin

Since Specialization

Citations

This map shows the geographic impact of Jianchang Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianchang Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianchang Lin more than expected).

Fields of papers citing papers by Jianchang Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianchang Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianchang Lin. The network helps show where Jianchang Lin may publish in the future.

Co-authorship network of co-authors of Jianchang Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Jianchang Lin. A scholar is included among the top collaborators of Jianchang Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianchang Lin. Jianchang Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods 2025 ·Therapeutic Innovation & Regulatory Science ·(unknown),(unknown),(unknown),Rachael Liu,Jianchang Lin	0
2	First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial 2025 ·Journal of Clinical Oncology ·Pasi A. Jänne,Bin-Chao Wang,Byoung Chul Cho,Jun Zhao,Juan Li,Maximilian J. Hochmair,Solange Peters,Benjamin Besse,Nick Pavlakis,Joel W. Neal,Terufumi Kato,Yi‐Long Wu,Danny Nguyen,(unknown),Jianchang Lin,Florin Vranceanu,Annette Szumski,Huamao Mark Lin,Robert J. Fram,Tony Mok	7
3	BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization 2025 ·Clinical Trials ·(unknown),Rachael Liu,Jianchang Lin,Ying Yuan	0
4	Bayesian model averaging for randomized dose optimization trials in multiple indications 2025 ·Journal of Biopharmaceutical Statistics ·Wei Wei,Jianchang Lin	0
5	A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants 2024 ·Investigational New Drugs ·Michael J. Hanley,Steven Zhang,Robert Griffin,Xiaochun Zhu,Robert J. Fram,Jianchang Lin,Karthik Venkatakrishnan,Neeraj Gupta	3
6	Incorporating external real-world data (RWD) in confirmatory adaptive design 2024 ·Journal of Biopharmaceutical Statistics ·(unknown),Jianchang Lin,(unknown),(unknown)	0
7	Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data 2024 ·Journal of Biopharmaceutical Statistics ·(unknown),Yunlong Yang,(unknown),Veronica Bunn,Jianchang Lin	0
8	507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC 2023 ·Annals of Oncology ·Pasi A. Jänne,(unknown),Byoung Chul Cho,Jun Zhao,Jiaqi Li,Maximilian J. Hochmair,Solange Peters,Benjamin Besse,Terufumi Kato,Yi‐Long Wu,(unknown),Jianchang Lin,Florin Vranceanu,Melanie Lin,Robert J. Fram,Tony Mok	16
9	Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison 2023 ·Lung Cancer ·Sai‐Hong Ignatius Ou,Huamao Mark Lin,Jin‐Liern Hong,Yu Yin,Shu Jin,Jianchang Lin,Minal Mehta,Pingkuan Zhang,Danny Nguyen,Joel W. Neal	4
10	Clinical value of neutrophil-to-lymphocyte ratio and prognostic nutritional index on prediction of occurrence and development of diabetic foot-induced sepsis 2023 ·Frontiers in Public Health ·(unknown),Yimin Chen,(unknown),Yu Fu,Jianchang Lin,Zhaohong Chen	11
11	Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations 2023 ·Lung Cancer ·Petros Christopoulos,(unknown),Jin‐Liern Hong,Huamao Mark Lin,Luis Hernández,Shu Jin,Min Tan,Irina Proskorovsky,Jianchang Lin,Pingkuan Zhang,Jyoti D. Patel,Sai‐Hong Ignatius Ou,Michael Thomas,Albrecht Stenzinger	3
12	Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol 2023 ·Therapeutic Innovation & Regulatory Science ·(unknown),Liwen Wu,Veronica Bunn,Qing Li,Jianchang Lin	6
13	Statistical methods of indirect comparison with real-world data for survival endpoint under non-proportional hazards 2022 ·Journal of Biopharmaceutical Statistics ·Zihan Lin,(unknown),(unknown),(unknown),Ai Ni,Jianchang Lin	1
14	Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team 2022 ·Annals of Translational Medicine ·Xiaoyun Li,(unknown),Kristine Broglio,Paul Bycott,(unknown),Qi Jiang,Jianchang Lin,Jingjing Ye,Jun Yin	4
15	Propensity‐score‐based meta‐analytic predictive prior for incorporating real‐world and historical data 2021 ·Statistics in Medicine ·(unknown),Veronica Bunn,(unknown),(unknown),Jianchang Lin,(unknown),(unknown)	31
16	Incorporating propensity scores for evidence synthesis under bayesian framework: review and recommendations for clinical studies 2021 ·Journal of Biopharmaceutical Statistics ·(unknown),Jianchang Lin,(unknown),(unknown)	14
17	Using Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect 2021 ·Statistics in Biopharmaceutical Research ·Qing Li,Jianchang Lin,Mengya Liu,Liwen Wu,(unknown)	12
18	1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions 2021 ·Annals of Oncology ·Petros Christopoulos,S-H.I. Ou,Jianchang Lin,(unknown),(unknown),Yu Yin,Veronica Bunn,Hui‐Ming Lin,Minal Mehta,Michael Thomas	2
19	Flexible Bayesian subgroup analysis in early and confirmatory trials 2020 ·Contemporary Clinical Trials ·Veronica Bunn,Rachael Liu,(unknown),Jianchang Lin,(unknown),(unknown)	5
20	Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials 2017 ·Contemporary Clinical Trials ·Jianchang Lin,Veronica Bunn	44

About Jianchang Lin

Jianchang Lin is a scholar working on Statistics and Probability, Management Science and Operations Research and Hematology, having authored 84 papers that have together received 1.0k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (44 papers), Lung Cancer Treatments and Mutations (21 papers) and Optimal Experimental Design Methods (19 papers). The work is most often cited by research in Statistics and Probability (276 citations), Hematology (182 citations) and Oncology (395 citations). Jianchang Lin has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Veronica Bunn, Shu Jin, Qing Li, Danny Nguyen, Minal Mehta, Huamao Mark Lin, Rachael Liu, Pasi A. Jänne, Suresh S. Ramalingam and James Chih‐Hsin Yang. Their work appears in journals such as Journal of Clinical Oncology, Blood and Biometrics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact